Edelman M J
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, USA.
Expert Rev Anticancer Ther. 2001 Aug;1(2):229-35. doi: 10.1586/14737140.1.2.229.
Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.
在接受早期非小细胞肺癌（NSCLC）完全切除的患者中，30%至60%将会死亡。术后辅助化疗尚未显示出明确的益处，并且在对NSCLC患者中存在的严重合并症患者进行术后化疗时存在重大困难。目前，多项试验正在评估术前化疗在I期和II期NSCLC中的作用。本文综述了这种方法的基本原理以及未来可能的发展。
Zotero 插件